Claudio Laudani/X
Aug 8, 2025, 15:28
Claudio Laudani: New Insights on P2Y12 Monotherapy in Antiplatelet Therapy
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on X:
”The landscape of antiplatelets has changed in the last decade, shifting from the initial focus on long-term DAPT to P2Y12 inhibitor monotherapy. In this review, we summarize the pharmacology and clinical evidence on antiplatelet montherapy.”
Read the full article here.
Title: Antiplatelet Monotherapies for Long-Term Secondary Prevention Following Percutaneous Coronary Intervention
Authors: Claudio Laudani, Daniele Giacoppo, Antonio Greco, Luis Ortega-Paz, Georges El Khoury, Davide Capodanno, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research
-
Jul 8, 2026, 19:25Luca Saba: Why Does the Same Patient Have Different Plaque in Different Arteries?
-
Jul 8, 2026, 19:25Luisa Weiss: Understanding the Molecular Differences Between Acute and Chronic Coronary Syndromes.